MediciNova (NASDAQ:MNOV) Given Buy Rating at D. Boral Capital
MediciNova (NASDAQ:MNOV – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They currently have a $9.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s target price indicates a potential upside of 480.65% from the company’s previous close. […]
